Vallon Pharmaceuticals, Inc. (VLON)
| Market Cap | 33.93M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| Shares Out | 5.71M |
| EPS (ttm) | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | June 11 |
| Last Price | $4.98 |
| Previous Close | $4.90 |
| Change ($) | 0.08 |
| Change (%) | 1.63% |
| Day's Open | 4.70 |
| Day's Range | 4.70 - 5.40 |
| Day's Volume | 294,974 |
| 52-Week Range | 3.61 - 9.90 |
- Company remains on track to report p ivotal data from lead program , ADAIR, in second half 2021
- Financial executive bringing over 20 years of experience in accounting, finance and management with a foundation established from big four accounting firm
Live video webcast with David Baker, President and CEO of Vallon on Tuesday, May 18, 2021 at 4:15 PM ET
David Baker, President and CEO of Vallon to participate in the virtual Advances in Neuropsychiatry Panel on A pril 29 th at 10:30 AM ET
- Ongoing ADAIR SEAL study on target for pivotal data readout in second half of 2021 - Target NDA filing in Q2 2022 for a potential abuse-deterrent alternative to commercially available IR amphetamines ...
Pre-market movers on Tuesday include ZOM stock, RIOT stock and AGC stock, following all sorts of big stock market news. The post Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tue...
- Pivotal data from lead program, ADAIR, expected in second half 2021
PHILADELPHIA, PA, March 03, 2021 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), a clinical-stage biopharmaceutical company primarily focused on the developm...
- Accomplished executive leader with more than 30 years of experience in finance and operations
PHILADELPHIA, PA, Feb. 12, 2021 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals Inc. (NASDAQ: VLON) (“Vallon” or the “Company”), a clinical-stage biopharmaceutical company primarily focused on the developmen...
PHILADELPHIA, PA, Feb. 09, 2021 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (the “Company”), a clinical-stage biopharmaceutical company primarily focused on the development of novel drugs that are ...
Vallon Pharmaceuticals, a biopharma developing abuse-deterrent prescription drugs for CNS disorders, announced terms for its IPO on Thursday.
Vallon Pharmaceuticals, Inc. has filed to go public with an IPO on the NASDAQ.
About VLON
Vallon Pharmaceuticals is a biopharmaceutical company primarily focused on the development and commercialization of proprietary biopharmaceutical products. We are developing prescription drugs for central nervous system (CNS) disorders and our current focus is the development of drugs with lower potential for abuse than currently available drugs. Our clinical-stage product currently under development is Abuse-Deterrent Amphetamine Immediate-Release, or ADAIR, a proprietary, abuse-deterrent oral formulation of immediate-release (short-acting) de... [Read more...]
| Industry Biotechnology | IPO Date Feb 10, 2021 |
| CEO David Baker | Employees 2 |
| Stock Exchange NASDAQ | Ticker Symbol VLON |